SCHEMBL19652124

SCHEMBL19652124

Cc1cnc(N2CCC(NC(=O)C(C)C)CC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
USP2 O75604 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
KDM5A P29375 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
ACACB O00763 1/20 0.40
ACKR3 P25106 1/20 0.39
JAK1 P23458 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19652283 0.88 CYP11B2 (0.45) MCHR1MEN1KMT2AMTNR1AMTNR1B
SCHEMBL19652277 0.86 MEN1 (0.55) GPR119MEN1KMT2AMTNR1AMTNR1B
SCHEMBL19658643 0.84 CKS1B (0.50) GPR119MEN1KMT2ATSHRALDH1A1
SCHEMBL19652118 0.79 KDM4E (0.64) MEN1KMT2ATSHRALDH1A1USP2
SCHEMBL12490730 0.76 OPRK1 (0.52) GPR119
SCHEMBL12525108 0.76 GPR119 (0.47) GPR119
SCHEMBL27808913 0.74 PANK3 (0.51) MCHR1GPR119CNR1CNR2KDM4E
SCHEMBL21551131 0.74 MEN1 (0.45) MEN1KMT2ATSHRALDH1A1USP2
SCHEMBL20152894 0.73 KDM4E (0.50) GPR119MEN1KMT2AALDH1A1USP2
SCHEMBL18248384 0.73 KDM4E (0.68) GPR119MEN1KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 MCHR1 2667/4885GPR119 988/4885MEN1 1364/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 MCHR1 2667/4885GPR119 988/4885MEN1 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.